...
首页> 外文期刊>International Journal of Pharmaceutical Sciences and Research >FORMULATION, ASSESSMENT AND COMPATIBILITY ANALYSIS OF DIFFERENT POLYMERS LOADED MICROSPHERES BY NON AQUEOUS SOLVENT EVAPORATION TECHNIQUE: IN VITRO-IN VIVO STUDY OF GLIBENCLAMIDE AS A MODEL DRUG
【24h】

FORMULATION, ASSESSMENT AND COMPATIBILITY ANALYSIS OF DIFFERENT POLYMERS LOADED MICROSPHERES BY NON AQUEOUS SOLVENT EVAPORATION TECHNIQUE: IN VITRO-IN VIVO STUDY OF GLIBENCLAMIDE AS A MODEL DRUG

机译:非水溶剂蒸发技术对负载聚合物的微球的制备,评价和相容性分析:阿糖胞苷作为模型药物的体外研究

获取原文

摘要

Glibenclamide is an oral anti-hyperglycemic agent designed intended for the management of non-insulin-dependent diabetes mellitus (NIDDM). In certain conditions conventional drug release pattern is not suitable similar to Diabetes mellitus, cardiovascular diseases and many more diseases, this present study has taken a challenge to formulate controlled release microspheres by using different polymers. An effort has been given to prepare controlled release microspheres along with Ethyl cellulose, Eudragit RS/RL100 and Methocel K15, 100M by using non-aqueous emulsion solvent evaporation method. UV-Spectrophotometric was applied to assay the drug content and in vitro dissolution studies according to USP paddle method and was carried out in Phosphate Buffer (pH 7.4) for 8 hours. The in-vitro release kinetics was studied in different mathematical release models. The best data fitted with the highest correlation coefficient (R2) for microspheres was obtained for Korsmeyer release model. The maximum and minimum release of drug was observed 90.99% and 71.98%. Percent of Actual drug entrapment varied from 7.89% to 15.36% and percent of Drug entrapment efficacy varied from 69.23% to 98.21%. The SEM, FTIR and DSC studies used to of confirmed good spheres and smooth surface as well as interaction along with drug and polymer. Different biochemical tests have done on albino rats which showed good results and it also proved that formulations have given sustained release effects. In-vitro-in vivo studies showed that Glibenclamide microspheres might be a good candidate as sustained drug delivery system for treating type II diabetic
机译:格列本脲是一种口服降糖药,旨在治疗非胰岛素依赖型糖尿病(NIDDM)。在某些情况下,传统的药物释放模式与糖尿病,心血管疾病和许多其他疾病不一样,因此本研究面临挑战,即使用不同的聚合物来配制控释微球。已经通过使用非水乳液溶剂蒸发法来努力与乙基纤维素,Eudragit RS / RL100和Methocel K15,100M一起制备控释微球。紫外分光光度法根据USP桨法用于测定药物含量和体外溶出度研究,并在磷酸盐缓冲液(pH 7.4)中进行8小时。在不同的数学释放模型中研究了体外释放动力学。对于Korsmeyer释放模型,获得了具有最高相关系数(R2)的微球的最佳数据。观察到药物的最大和最小释放为90.99%和71.98%。实际药物截留百分比在7.89%至15.36%之间,药物截留效力百分比在69.23%至98.21%之间。 SEM,FTIR和DSC研究用于确认良好的球体和光滑的表面以及与药物和聚合物的相互作用。对白化病大鼠进行了不同的生化测试,结果显示了良好的效果,也证明了该制剂具有缓释作用。体内体外研究表明格列本脲微球可能是治疗II型糖尿病的持续药物输送系统的良好候选者

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号